Protocol summary

Study aim
Determining the effectiveness of anti-anxiety drug therapy (buspirone and mirtazapine) on anxiety and gastrointestinal symptoms in patients with functional dyspepsia with symptoms of postprandial discomfort syndrome
Design
A controlled, parallel-group, single-blind, randomized, phase 2-3 clinical trial of 120 patients. Randomization by block method and random unit of patient number
Settings and conduct
This study will be performed in Birjand University of Medical Sciences(gastroenterology clinic)in the fall of 1400.120 patients are divided into 3groups of 40:group(1 receiving buspirone),group(2 mirtazapine)and group(3 control).Each group is treated and monitored with doses of drugs for 1month.Before and at the end of the first month,results are recorded and analyzed.one-blinded -patients have no information about the medication
Participants/Inclusion and exclusion criteria
Inclusion:Age,Willingness to participate•No psychological treatment,other structural or functional gastrointestinal disorders at the same time,other organic disease,alcohol and drug use,personality disorder and psychosis,danger symptoms•Stability of medication;Exclusion:Psychotic disorder or other concomitant GI disorder•personality disorder•Dangerous symptoms•Withdrawal of the patient,Failure to follow recommendations
Intervention groups
120 patients divided into three groups of 40:group (1 buspirone), group (2 mirtazapine) and group (3 control). Each group is treated and monitored with doses of drugs for1month.Before and at the end of the first month, clinical results are recorded and analyzed
Main outcome variables
Functional dyspepsia ; severity of anxiety ; severity of dyspeptic symptoms

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20210724051972N1
Registration date: 2022-12-29, 1401/10/08
Registration timing: retrospective

Last update: 2022-12-29, 1401/10/08
Update count: 0
Registration date
2022-12-29, 1401/10/08
Registrant information
Name
Mahdieh Khorashadizade
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 56 3234 0464
Email address
khorashadi.m@yahoo.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-11-01, 1400/08/10
Expected recruitment end date
2022-03-01, 1400/12/10
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Investigation of the effectiveness of anti-anxiety medication (Buspirone and Mirtazapine) on anxiety and gastrointestinal symptoms of functional dyspepsia patients with postprandial discomfort syndrome
Public title
Investigation of the effectiveness of Buspirone and Mirtazapine on functional dyspepsia
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Willingness to participate in the study after explaining all the objectives of the research and the advantages and disadvantages of the methods Failure to receive psychological treatment before entering the study Lack of other structural or functional gastrointestinal disorders No other organic disease Possibility to keep the type and amount of drug used during the research period if the drug is used No alcohol and drugs No psychotic disorder and personality disorder Absence of alarm signs such as gastrointestinal bleeding, blood in the stool, fever, weight loss, anemia, nocturnal diarrhea, severe heartburn Age between 18 and 50 years
Exclusion criteria:
Age
From 18 years old to 50 years old
Gender
Both
Phase
2-3
Groups that have been masked
  • Participant
Sample size
Target sample size: 120
Randomization (investigator's opinion)
Randomized
Randomization description
method of randomization: block unit of randomization: Number of patients In this study, the randomized block method is used as six blocks with equal proportions of groups (36 different permutations - abcabc, abcacb, abcbca, ..., cabcab) from one to thirty-six numbering and then random selection of blocks are performed using the production of a random number between 1 and 36 The packages are printed and placed in separate envelopes, and according to the order of the person who provides the drug, she provides the desired letter from the drug group or the pharmaceutical form. In this study, we will use the restricted randomization method (blockrandomization). Blocking is usually used in order to create a balance in the number of samples allocated to each of the study groups. This feature helps the researchers so that the number of samples allocated to each of the studied groups is equal. The size of all the blocks is equal and we will have 6 blocks in this three-group experiment. The randomization tool is also from the production software. Random allocation software is used. In addition to simple randomization, these random sequence generation softwares are capable of generating random sequences using the blocking method. For concealment, we use allocation concealment, which is the method used. It refers to the implementation of random sequence on the participants in the study, so that the allocated group is not known before the allocation of the individual. By using opaque sealed envelopes with random sequence (Sequentially numbered, sealed, opaque envelopes). In this method, each of the random sequences created is recorded on a card and the cards are placed in the letter envelopes in order. In order to maintain a random sequence, the outer surface of the envelopes is numbered in the same order. Finally, the lid of the letter envelopes is glued and placed in a box. At the time of registration of the participants, based on the order in which the eligible participants entered the study, one of the envelopes will be opened and the assigned group of that participant will be revealed.
Blinding (investigator's opinion)
Single blinded
Blinding description
The participants do not know which treatment they will receive, and the referring physician also does not know about the assigned treatment. The person interviewing the patients does not know about the treatment received by the patients. Random allocation list that uses the software Random Allocation Software is produced in random permutation blocks and is available to the assistant, based on which the drugs will be allocated to the diseases in order. It will be explained to the participants that they are in a study and the groups will be introduced and mentioned that they will be randomly assigned to one of the groups. By using opaque sealed envelopes with random sequence (Sequentially numbered, sealed, opaque envelopes). In this method, each of the random sequences created is recorded on a card and the cards are placed in the letter envelopes in order. In order to maintain a random sequence, the outer surface of the envelopes is numbered in the same order. Finally, the lid of the letter envelopes is glued and placed in a box. At the time of registration of the participants, based on the order in which the eligible participants entered the study, one of the envelopes will be opened and the assigned group of that participant will be revealed.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Birjand University of Medical Sciences
Street address
Ghafari Ave, Birjand university of medical sciences, Birjand city
City
Birjand
Province
South Khorasan
Postal code
9717853577
Approval date
2021-09-14, 1400/06/23
Ethics committee reference number
IR.BUMS.REC.1400.204

Health conditions studied

1

Description of health condition studied
Functional dyspepsia
ICD-10 code
K30
ICD-10 code description
Functional dyspepsia,Mirtazapine,Buspirone,Anxiety

Primary outcomes

1

Description
The severity of dyspepsia symptoms in the three groups receiving buspirone, mirtazapine and the control group
Timepoint
The severity of dyspepsia symptoms in the three groups receiving buspirone, mirtazapine before the intervention and one month after the intervention and three months after the intervention and in the control group before the intervention and one month after the intervention
Method of measurement
patient assessment of upper gastrointestinal symptom severity index questionnaire(pagi-sym)

2

Description
Beck anxiety score in three groups receiving buspirone, mirtazapine and control group
Timepoint
Determining and comparing the mean score of Beck anxiety in the two groups receiving buspirone, receiving mirtazapine before the intervention, one month after the intervention and three months after the intervention and in the control group before the intervention and one month after the intervention
Method of measurement
Beck Anxiety Questionnaire

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: First - Buspirone receiving group with a dose of 5 mg three times a day for three months (Buspirax-brand name, Tehrandaroo factory)
Category
Treatment - Drugs

2

Description
Control group: First - group receiving Pantoprazole at a dose of 40 mg daily for three months(Nolpaza-brand name, Actoverco)
Category
N/A

3

Description
Intervention group: Second - the group receiving Mirtazapine at a dose of 7.5 mg nightly for three months (Mirtazapine-brand name)
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
One of the affiliated units of Birjand University of Medical Sciences (gastroenterology clinic)
Full name of responsible person
Tahmine Tavakoli
Street address
Gastroenterology Clinic - Taleghani 1 Sepideh Building 3rd Floor Unit 5
City
Birjand
Province
South Khorasan
Postal code
9717433768
Phone
+98 56 3243 6200
Email
khorashadi.m@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Birjand University of Medical Sciences
Full name of responsible person
Dr Tooba Kazemi
Street address
South Khorasan, Birjand, Ghaffari St., Deputy of Education and Research Building-Second Floor-Deputy of Research and Technology
City
Birjand
Province
South Khorasan
Postal code
۹۷۱۷۸۵۳۵۷۷
Phone
+98 56 3238 1200
Email
research@bums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Birjand University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Birjand University of Medical Sciences
Full name of responsible person
Dr Tahmineh Tavakoli
Position
Associate Professor
Latest degree
Medical doctor
Other areas of specialty/work
Internal Medicine
Street address
Ghaffari St., Valiasr Hospital
City
Birjand
Province
South Khorasan
Postal code
۹۷۱۷۸۵۳۵۷۷
Phone
+98 56 3243 6200
Email
tahminetavakoli93238@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Birjand University of Medical Sciences
Full name of responsible person
Mahdieh Khorashadizade
Position
stugent- Intern
Latest degree
Bachelor
Other areas of specialty/work
General Practitioner
Street address
Ghaffari St., Central Organization of Birjand University of Medical Sciences
City
Birjand
Province
South Khorasan
Postal code
۹۷۱۷۸۵۳۵۷۷
Phone
+98 56 3239 5000
Email
khorashadi.m@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Birjand University of Medical Sciences
Full name of responsible person
Mahdieh Khorashadizade
Position
stugent- Intern
Latest degree
Bachelor
Other areas of specialty/work
General Practitioner
Street address
Ghaffari St., Central Organization of Birjand University of Medical Sciences
City
Birjand
Province
South Khorasan
Postal code
۹۷۱۷۸۵۳۵۷۷
Phone
+98 56 3239 5000
Email
khorashadi.m@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
There is no more information
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
The main outcome of the study
When the data will become available and for how long
One year after the results are published
To whom data/document is available
people working in academic institutions or people working in businesses
Under which criteria data/document could be used
Related researchers in this field
From where data/document is obtainable
Mahdieh Khorashadizade khorashadi.m@yahoo.com
What processes are involved for a request to access data/document
Give an email and after checking the applicant's profile, send the information
Comments
Loading...